Annual SG&A
$30.91 M
+$3.72 M+13.68%
31 December 2023
Summary:
Celldex Therapeutics annual selling, general & administrative expenses is currently $30.91 million, with the most recent change of +$3.72 million (+13.68%) on 31 December 2023. During the last 3 years, it has risen by +$16.46 million (+113.85%). CLDX annual SG&A is now -14.08% below its all-time high of $35.98 million, reached on 31 December 2016.CLDX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$10.05 M
+$926.00 K+10.14%
01 September 2024
Summary:
Celldex Therapeutics quarterly selling, general & administrative expenses is currently $10.05 million, with the most recent change of +$926.00 thousand (+10.14%) on 01 September 2024. Over the past year, it has increased by +$1.83 million (+22.30%). CLDX quarterly SG&A is now -15.73% below its all-time high of $11.93 million, reached on 31 December 2016.CLDX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$5.80 B
-$154.08 M-2.73%
01 September 2024
Summary:
Celldex Therapeutics TTM selling, general & administrative expenses is currently -$5.80 billion, with the most recent change of -$154.08 million (-2.73%) on 01 September 2024. Over the past year, it has dropped by -$5.83 billion (-20328.28%). CLDX TTM SG&A is now -199957.69% below its all-time high of $37.12 million, reached on 01 September 2024.CLDX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.7% | +22.3% | -10000.0% |
| 3 y3 years | +113.8% | +72.7% | -10000.0% |
| 5 y5 years | +60.4% | +195.4% | -10000.0% |
CLDX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +113.8% | at high | +72.7% | -32.2% | at low |
| 5 y | 5 years | at high | +113.8% | at high | +212.3% | -47.4% | at low |
| alltime | all time | -14.1% | +1527.0% | -15.7% | +327.6% | <-9999.0% | at low |
Celldex Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.05 M(+10.1%) | $37.12 M(+5.2%) |
| June 2024 | - | $9.13 M(+0.3%) | $35.28 M(+5.7%) |
| Mar 2024 | - | $9.10 M(+3.1%) | $33.38 M(+8.0%) |
| Dec 2023 | $30.91 M(+13.7%) | $8.83 M(+7.4%) | $30.91 M(+7.8%) |
| Sept 2023 | - | $8.22 M(+13.8%) | $28.68 M(+6.3%) |
| June 2023 | - | $7.22 M(+8.8%) | $26.99 M(+0.2%) |
| Mar 2023 | - | $6.64 M(+0.6%) | $26.92 M(-1.0%) |
| Dec 2022 | $27.20 M(+32.7%) | $6.60 M(+1.0%) | $27.20 M(+1.3%) |
| Sept 2022 | - | $6.53 M(-8.7%) | $26.84 M(+2.7%) |
| June 2022 | - | $7.15 M(+3.5%) | $26.13 M(+12.2%) |
| Mar 2022 | - | $6.91 M(+10.7%) | $23.28 M(+13.6%) |
| Dec 2021 | $20.49 M(+41.7%) | $6.24 M(+7.2%) | $20.49 M(+14.6%) |
| Sept 2021 | - | $5.82 M(+35.2%) | $17.87 M(+13.9%) |
| June 2021 | - | $4.31 M(+4.5%) | $15.69 M(+5.2%) |
| Mar 2021 | - | $4.12 M(+13.7%) | $14.91 M(+3.1%) |
| Dec 2020 | $14.46 M(-6.3%) | $3.62 M(-0.5%) | $14.46 M(+2.9%) |
| Sept 2020 | - | $3.64 M(+3.2%) | $14.05 M(+1.7%) |
| June 2020 | - | $3.53 M(-3.8%) | $13.82 M(-2.7%) |
| Mar 2020 | - | $3.67 M(+13.9%) | $14.20 M(-8.0%) |
| Dec 2019 | $15.43 M(-19.9%) | $3.22 M(-5.4%) | $15.43 M(-6.7%) |
| Sept 2019 | - | $3.40 M(-12.9%) | $16.54 M(-1.9%) |
| June 2019 | - | $3.91 M(-20.2%) | $16.86 M(-9.2%) |
| Mar 2019 | - | $4.90 M(+13.0%) | $18.57 M(-3.6%) |
| Dec 2018 | $19.27 M(-22.9%) | $4.33 M(+16.4%) | $19.27 M(-7.5%) |
| Sept 2018 | - | $3.72 M(-33.8%) | $20.83 M(-7.2%) |
| June 2018 | - | $5.62 M(+0.5%) | $22.45 M(-3.9%) |
| Mar 2018 | - | $5.59 M(-5.1%) | $23.37 M(-6.5%) |
| Dec 2017 | $25.00 M(-30.5%) | $5.89 M(+10.3%) | $25.00 M(-19.4%) |
| Sept 2017 | - | $5.35 M(-18.2%) | $31.04 M(-4.9%) |
| June 2017 | - | $6.53 M(-9.6%) | $32.64 M(-3.7%) |
| Mar 2017 | - | $7.23 M(-39.4%) | $33.90 M(-5.8%) |
| Dec 2016 | $35.98 M(+6.3%) | $11.93 M(+71.7%) | $35.98 M(+2.4%) |
| Sept 2016 | - | $6.95 M(-10.8%) | $35.12 M(-4.2%) |
| June 2016 | - | $7.79 M(-16.3%) | $36.66 M(-1.1%) |
| Mar 2016 | - | $9.31 M(-16.0%) | $37.05 M(+9.5%) |
| Dec 2015 | $33.84 M(+64.1%) | $11.08 M(+30.5%) | $33.84 M(+16.6%) |
| Sept 2015 | - | $8.49 M(+3.7%) | $29.01 M(+13.6%) |
| June 2015 | - | $8.18 M(+34.4%) | $25.53 M(+15.4%) |
| Mar 2015 | - | $6.09 M(-2.6%) | $22.13 M(+7.3%) |
| Dec 2014 | $20.62 M(+39.3%) | $6.25 M(+24.9%) | $20.62 M(+8.3%) |
| Sept 2014 | - | $5.00 M(+4.5%) | $19.05 M(+8.1%) |
| June 2014 | - | $4.79 M(+4.5%) | $17.62 M(+8.5%) |
| Mar 2014 | - | $4.58 M(-2.0%) | $16.25 M(+9.8%) |
| Dec 2013 | $14.80 M(+47.8%) | $4.68 M(+30.7%) | $14.80 M(+15.9%) |
| Sept 2013 | - | $3.58 M(+4.9%) | $12.77 M(+6.2%) |
| June 2013 | - | $3.41 M(+8.7%) | $12.03 M(+11.0%) |
| Mar 2013 | - | $3.14 M(+18.7%) | $10.84 M(+8.2%) |
| Dec 2012 | $10.02 M(+9.0%) | $2.64 M(-6.7%) | $10.02 M(+239.0%) |
| Sept 2012 | - | $2.83 M(+27.8%) | $2.95 M(-37.3%) |
| June 2012 | - | $2.22 M(-4.2%) | $4.71 M(-0.4%) |
| Mar 2012 | - | $2.32 M(-152.5%) | $4.73 M(-0.4%) |
| Dec 2011 | $9.19 M(-11.4%) | -$4.42 M(-196.2%) | $4.75 M(-59.4%) |
| Sept 2011 | - | $4.59 M(+105.0%) | $11.70 M(+22.8%) |
| June 2011 | - | $2.24 M(-4.1%) | $9.53 M(-3.6%) |
| Mar 2011 | - | $2.34 M(-7.7%) | $9.88 M(-4.8%) |
| Dec 2010 | $10.38 M(-39.4%) | $2.53 M(+4.5%) | $10.38 M(-27.3%) |
| Sept 2010 | - | $2.42 M(-6.6%) | $14.27 M(-9.1%) |
| June 2010 | - | $2.59 M(-8.6%) | $15.69 M(-5.5%) |
| Mar 2010 | - | $2.83 M(-55.8%) | $16.61 M(-3.0%) |
| Dec 2009 | $17.12 M(+16.1%) | $6.42 M(+66.7%) | $17.12 M(+25.7%) |
| Sept 2009 | - | $3.85 M(+9.7%) | $13.62 M(-2.5%) |
| June 2009 | - | $3.51 M(+5.1%) | $13.98 M(-7.3%) |
| Mar 2009 | - | $3.34 M(+14.3%) | $15.08 M(+2.1%) |
| Dec 2008 | $14.75 M(+113.6%) | $2.92 M(-30.5%) | $14.77 M(-0.7%) |
| Sept 2008 | - | $4.21 M(-8.7%) | $14.87 M(+24.2%) |
| June 2008 | - | $4.61 M(+51.9%) | $11.97 M(+42.3%) |
| Mar 2008 | - | $3.03 M(+0.4%) | $8.41 M(+21.8%) |
| Dec 2007 | $6.91 M(-27.8%) | $3.02 M(+131.4%) | $6.91 M(-8.2%) |
| Sept 2007 | - | $1.31 M(+24.5%) | $7.52 M(-6.4%) |
| June 2007 | - | $1.05 M(-31.3%) | $8.04 M(-11.7%) |
| Mar 2007 | - | $1.53 M(-58.0%) | $9.10 M(-4.8%) |
| Dec 2006 | $9.56 M | $3.64 M(+100.1%) | $9.56 M(+26.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2006 | - | $1.82 M(-14.1%) | $7.58 M(+2.0%) |
| June 2006 | - | $2.12 M(+6.5%) | $7.43 M(+3.6%) |
| Mar 2006 | - | $1.99 M(+20.3%) | $7.17 M(+4.0%) |
| Dec 2005 | $6.89 M(+23.7%) | $1.65 M(-1.0%) | $6.89 M(-1.0%) |
| Sept 2005 | - | $1.67 M(-10.3%) | $6.96 M(+5.8%) |
| June 2005 | - | $1.86 M(+8.8%) | $6.58 M(+9.9%) |
| Mar 2005 | - | $1.71 M(-0.5%) | $5.99 M(+7.5%) |
| Dec 2004 | $5.57 M(+4.1%) | $1.72 M(+33.2%) | $5.57 M(+7.1%) |
| Sept 2004 | - | $1.29 M(+1.6%) | $5.20 M(-2.5%) |
| June 2004 | - | $1.27 M(-1.7%) | $5.34 M(-1.5%) |
| Mar 2004 | - | $1.29 M(-4.3%) | $5.42 M(+1.3%) |
| Dec 2003 | $5.35 M(-4.3%) | $1.35 M(-5.1%) | $5.35 M(-0.8%) |
| Sept 2003 | - | $1.42 M(+5.3%) | $5.39 M(+1.9%) |
| June 2003 | - | $1.35 M(+10.4%) | $5.30 M(-6.0%) |
| Mar 2003 | - | $1.22 M(-12.1%) | $5.63 M(+0.7%) |
| Dec 2002 | $5.59 M(+13.8%) | $1.39 M(+5.1%) | $5.59 M(+2.3%) |
| Sept 2002 | - | $1.33 M(-21.4%) | $5.46 M(+0.1%) |
| June 2002 | - | $1.69 M(+42.3%) | $5.46 M(+10.1%) |
| Mar 2002 | - | $1.19 M(-6.3%) | $4.96 M(-0.6%) |
| Dec 2001 | $4.91 M(+2.2%) | $1.27 M(-4.3%) | $4.99 M(-6.5%) |
| Sept 2001 | - | $1.32 M(+11.2%) | $5.34 M(+5.4%) |
| June 2001 | - | $1.19 M(-2.1%) | $5.07 M(+3.0%) |
| Mar 2001 | - | $1.21 M(-24.7%) | $4.92 M(+2.3%) |
| Dec 2000 | $4.81 M(+12.3%) | $1.61 M(+53.6%) | $4.81 M(+0.7%) |
| Sept 2000 | - | $1.05 M(+0.8%) | $4.78 M(+5.5%) |
| June 2000 | - | $1.04 M(-5.5%) | $4.52 M(+0.9%) |
| Mar 2000 | - | $1.10 M(-30.2%) | $4.48 M(+2.3%) |
| Dec 1999 | $4.28 M(+12.6%) | $1.58 M(+97.5%) | $4.38 M(+4.3%) |
| Sept 1999 | - | $800.00 K(-20.0%) | $4.20 M(-2.3%) |
| June 1999 | - | $1.00 M(0.0%) | $4.30 M(+7.5%) |
| Mar 1999 | - | $1.00 M(-28.6%) | $4.00 M(+8.1%) |
| Dec 1998 | $3.80 M(+8.6%) | $1.40 M(+55.6%) | $3.70 M(+19.4%) |
| Sept 1998 | - | $900.00 K(+28.6%) | $3.10 M(0.0%) |
| June 1998 | - | $700.00 K(0.0%) | $3.10 M(-11.4%) |
| Mar 1998 | - | $700.00 K(-12.5%) | $3.50 M(-2.8%) |
| Dec 1997 | $3.50 M(-46.2%) | $800.00 K(-11.1%) | $3.60 M(-14.3%) |
| Sept 1997 | - | $900.00 K(-18.2%) | $4.20 M(0.0%) |
| June 1997 | - | $1.10 M(+37.5%) | $4.20 M(-33.3%) |
| Mar 1997 | - | $800.00 K(-42.9%) | $6.30 M(-3.1%) |
| Dec 1996 | $6.50 M(+10.2%) | $1.40 M(+55.6%) | $6.50 M(-3.0%) |
| Sept 1996 | - | $900.00 K(-71.9%) | $6.70 M(-9.5%) |
| June 1996 | - | $3.20 M(+220.0%) | $7.40 M(+34.5%) |
| Mar 1996 | - | $1.00 M(-37.5%) | $5.50 M(-6.8%) |
| Dec 1995 | $5.90 M(+1.7%) | $1.60 M(0.0%) | $5.90 M(+5.4%) |
| Sept 1995 | - | $1.60 M(+23.1%) | $5.60 M(+5.7%) |
| June 1995 | - | $1.30 M(-7.1%) | $5.30 M(-7.0%) |
| Mar 1995 | - | $1.40 M(+7.7%) | $5.70 M(-1.7%) |
| Dec 1994 | $5.80 M(-63.7%) | $1.30 M(0.0%) | $5.80 M(-30.1%) |
| Sept 1994 | - | $1.30 M(-23.5%) | $8.30 M(-25.9%) |
| June 1994 | - | $1.70 M(+13.3%) | $11.20 M(-17.6%) |
| Mar 1994 | - | $1.50 M(-60.5%) | $13.60 M(-15.0%) |
| Dec 1993 | $16.00 M(+58.4%) | $3.80 M(-9.5%) | $16.00 M(+31.1%) |
| Sept 1993 | - | $4.20 M(+2.4%) | $12.20 M(+2.5%) |
| June 1993 | - | $4.10 M(+5.1%) | $11.90 M(+6.3%) |
| Mar 1993 | - | $3.90 M(0.0%) | $11.20 M(-23.8%) |
| Dec 1992 | $10.10 M(-26.3%) | - | - |
| Oct 1992 | - | $3.90 M(+14.7%) | $14.70 M(+4.3%) |
| July 1992 | - | $3.40 M(-12.8%) | $14.10 M(+2.9%) |
| Apr 1992 | - | $3.90 M(+11.4%) | $13.70 M(+5.4%) |
| Apr 1992 | $13.70 M(+6.2%) | - | - |
| Jan 1992 | - | $3.50 M(+6.1%) | $13.00 M(+2.4%) |
| Oct 1991 | - | $3.30 M(+10.0%) | $12.70 M(+0.8%) |
| July 1991 | - | $3.00 M(-6.3%) | $12.60 M(-2.3%) |
| Apr 1991 | $12.90 M(+12.2%) | $3.20 M(0.0%) | $12.90 M(+1.6%) |
| Jan 1991 | - | $3.20 M(0.0%) | $12.70 M(-0.8%) |
| Oct 1990 | - | $3.20 M(-3.0%) | $12.80 M(+33.3%) |
| July 1990 | - | $3.30 M(+10.0%) | $9.60 M(+52.4%) |
| Apr 1990 | $11.50 M(+38.6%) | $3.00 M(-9.1%) | $6.30 M(+90.9%) |
| Jan 1990 | - | $3.30 M | $3.30 M |
| Apr 1989 | $8.30 M(+36.1%) | - | - |
| Apr 1988 | $6.10 M(+64.9%) | - | - |
| Apr 1987 | $3.70 M(+94.7%) | - | - |
| Apr 1986 | $1.90 M | - | - |
FAQ
- What is Celldex Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Celldex Therapeutics?
- What is Celldex Therapeutics annual SG&A year-on-year change?
- What is Celldex Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly SG&A year-on-year change?
- What is Celldex Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Celldex Therapeutics?
- What is Celldex Therapeutics TTM SG&A year-on-year change?
What is Celldex Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of CLDX is $30.91 M
What is the all time high annual SG&A for Celldex Therapeutics?
Celldex Therapeutics all-time high annual selling, general & administrative expenses is $35.98 M
What is Celldex Therapeutics annual SG&A year-on-year change?
Over the past year, CLDX annual selling, general & administrative expenses has changed by +$3.72 M (+13.68%)
What is Celldex Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of CLDX is $10.05 M
What is the all time high quarterly SG&A for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly selling, general & administrative expenses is $11.93 M
What is Celldex Therapeutics quarterly SG&A year-on-year change?
Over the past year, CLDX quarterly selling, general & administrative expenses has changed by +$1.83 M (+22.30%)
What is Celldex Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of CLDX is -$5.80 B
What is the all time high TTM SG&A for Celldex Therapeutics?
Celldex Therapeutics all-time high TTM selling, general & administrative expenses is $37.12 M
What is Celldex Therapeutics TTM SG&A year-on-year change?
Over the past year, CLDX TTM selling, general & administrative expenses has changed by -$5.83 B (-20328.28%)